Changing the mechanism of action may offer more durable disease control for patients with PsA who do not respond to an initial TNF inhibitor.

BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and ...

Maternal exposure to TNF inhibition does not significantly increase infection risk in newborns, according to findings ...

Patients with axial spondyloarthritis (axSpA) treated with tumor necrosis factor (TNF) inhibitors were at significantly lower risk for hip and spine fractures compared with those receiving only ...

While the link between TNF inhibitor use during pregnancy/postpartum and serious infection risk was not statistically significant, an increased risk cannot be ruled out.

Approximately two-thirds of patients with Crohn's disease who initially responded to tumor necrosis factor (TNF) inhibitors lost response by the third year of treatment, a population-based ...

In certain patients, JAK inhibitor rescue medications seem to be more effective, researche ...

“We’re witnessing a renaissance in cytokine targeting,” says Dr. Emily Rhodes, immunologist at the Stanford Institute for Translational Medicine. “And TNF-α is still the most contested—and the most ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Patients with axial SpA treated with TNF inhibitors had ...

R Dr Eneas de Carvalho Aguiar 470, Instituto de Medicina Tropical (IMT), Cerqueira Cesar, São Paulo, SP, 05403 903, Brazil Tel.: +55 11 3061 7457 Fax: +55 11 3081 7190 mahong@usp.br Establishing that ...